BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Borbath I, Leclercq IA, Sempoux C, Abarca-quinones J, Desaeger C, Horsmans Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chemico-Biological Interactions 2010;183:238-48. [DOI: 10.1016/j.cbi.2009.10.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Thangavel P, Vaiyapuri M. Antiproliferative and apoptotic effects of naringin on diethylnitrosamine induced hepatocellular carcinoma in rats. Biomedicine & Aging Pathology 2013;3:59-64. [DOI: 10.1016/j.biomag.2013.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
2 Thoolen B, Ten Kate FJ, van Diest PJ, Malarkey DE, Elmore SA, Maronpot RR. Comparative histomorphological review of rat and human hepatocellular proliferative lesions. J Toxicol Pathol 2012;25:189-99. [PMID: 22988337 DOI: 10.1293/tox.25.189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
3 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
4 Nasr M, Selima E, Hamed O, Kazem A. Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice. Eur J Pharmacol. 2014;723:267-275. [PMID: 24291100 DOI: 10.1016/j.ejphar.2013.11.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
5 Wagner M, Doblas S, Poté N, Lambert SA, Ronot M, Garteiser P, Paradis V, Vilgrain V, Van Beers BE. Comparison of pulsed and oscillating gradient diffusion-weighted MRI for characterizing hepatocellular nodules in liver cirrhosis: ex vivo study in a rat model. J Magn Reson Imaging 2020;51:1065-74. [PMID: 31507025 DOI: 10.1002/jmri.26919] [Reference Citation Analysis]
6 Alarcón-Sánchez BR, Pérez-Carreón JI, Villa-Treviño S, Arellanes-Robledo J. Molecular alterations that precede the establishment of the hallmarks of cancer: An approach on the prevention of hepatocarcinogenesis. Biochem Pharmacol 2021;:114818. [PMID: 34757033 DOI: 10.1016/j.bcp.2021.114818] [Reference Citation Analysis]
7 Ciccarelli O, Colson A, De Saeger C, Reding R, Sempoux C, Leclercq IA, Stärkel P. Tumoral response and tumoral phenotypic changes in a rat model of diethylnitrosamine-induced hepatocellular carcinoma after salirasib and sorafenib administration. Onco Targets Ther 2018;11:7143-53. [PMID: 30410370 DOI: 10.2147/OTT.S176903] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Papanagnou P, Papadopoulos GE, Stivarou T, Pappas A. Toward fully exploiting the therapeutic potential of marketed pharmaceuticals: the use of octreotide and chloroquine in oncology. Onco Targets Ther 2019;12:319-39. [PMID: 30643430 DOI: 10.2147/OTT.S182685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
9 Saif MW. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy 2016;17:443-56. [DOI: 10.1517/14656566.2016.1127914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Golla K, Cherukuvada B, Ahmed F, Kondapi AK. Efficacy, safety and anticancer activity of protein nanoparticle-based delivery of doxorubicin through intravenous administration in rats. PLoS One. 2012;7:e51960. [PMID: 23284832 DOI: 10.1371/journal.pone.0051960] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
11 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
12 Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 2010;8:109. [PMID: 21047421 DOI: 10.1186/1479-5876-8-109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
13 Bo Q, Yang F, Li Y, Meng X, Zhang H, Zhou Y, Ling S, Sun D, Lv P, Liu L, Shi P, Tian C. Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues. Cell Discov 2022;8:47. [PMID: 35595746 DOI: 10.1038/s41421-022-00405-2] [Reference Citation Analysis]
14 Golla K, Bhaskar C, Ahmed F, Kondapi AK. A target-specific oral formulation of Doxorubicin-protein nanoparticles: efficacy and safety in hepatocellular cancer. J Cancer 2013;4:644-52. [PMID: 24155776 DOI: 10.7150/jca.7093] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
15 Chen X, Zhang XY, Shen Y, Fan LL, Ren ML, Wu YP. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. Oncotarget 2016;7:83451-61. [PMID: 27825139 DOI: 10.18632/oncotarget.13120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lequoy M, Desbois-mouthon C, Wendum D, Gupta V, Blachon J, Scatton O, Dumont S, Bonnemaire M, Schmidlin F, Rosmorduc O, Fartoux L. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis. Histopathology 2017;70:492-8. [DOI: 10.1111/his.13034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]